Pasithea Therapeutics (KTTA)CEO sold ~$792
Tiago Marques, CEO at Pasithea Therapeutics, sold ~$792 of Pasithea Therapeutics shares.
- ~$792
- Approx. value · 960 sh @ $0.825
- 40K
- Holds after · shares reported
- Traded
- May 12, 2025
- Filed
- May 15, 2025
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Pasithea Therapeutics
For Pasithea Therapeutics, OQRO holds 1 fund holdings report (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its KTTA page.
Other recent filings by Tiago Marques, Chief Executive Officer
The full history of Tiago Marques, Chief Executive Officer is on the profile page.
How this filing works
Other disclosures at Pasithea Therapeutics
- SEC Form 13F-HRAug 14, 2026
- SEC Form 4Jun 22, 2026
- SEC Form 13F-HRMay 15, 2026
- SEC Form 4Dec 1, 2025
- SEC Form 4Dec 1, 2025
- SEC Form 4Dec 1, 2025
Everything OQRO holds on this company is on its KTTA page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO Pro is a paid subscription. You see the price before you pay
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data